292 related articles for article (PubMed ID: 18587251)
21. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
22. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment.
Tada Y; Wada M; Kuroiwa K; Kinugawa N; Harada T; Nagayama J; Nakagawa M; Naito S; Kuwano M
Clin Cancer Res; 2000 Dec; 6(12):4618-27. PubMed ID: 11156211
[TBL] [Abstract][Full Text] [Related]
23. DBC2 gene is silenced by promoter methylation in bladder cancer.
Shi Y; Chen JY; Yang J; Li B; Chen ZH; Xiao CG
Urol Oncol; 2008; 26(5):465-9. PubMed ID: 18640857
[TBL] [Abstract][Full Text] [Related]
24. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features.
Maruyama R; Toyooka S; Toyooka KO; Harada K; Virmani AK; Zöchbauer-Müller S; Farinas AJ; Vakar-Lopez F; Minna JD; Sagalowsky A; Czerniak B; Gazdar AF
Cancer Res; 2001 Dec; 61(24):8659-63. PubMed ID: 11751381
[TBL] [Abstract][Full Text] [Related]
25. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
26. Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.
Wu JY; Wang J; Lai JC; Cheng YW; Yeh KT; Wu TC; Chen CY; Lee H
Ann Surg Oncol; 2008 Nov; 15(11):3272-7. PubMed ID: 18712569
[TBL] [Abstract][Full Text] [Related]
27. A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer.
Müller HM; Widschwendter A; Fiegl H; Goebel G; Wiedemair A; Müller-Holzner E; Marth C; Widschwendter M
Cancer Lett; 2004 Jun; 209(2):231-6. PubMed ID: 15159026
[TBL] [Abstract][Full Text] [Related]
28. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer.
Brabender J; Arbab D; Huan X; Vallböhmer D; Grimminger P; Ling F; Neiss S; Bollschweiler E; Schneider PM; Hölscher AH; Metzger R
Ann Surg Oncol; 2009 May; 16(5):1378-83. PubMed ID: 19224282
[TBL] [Abstract][Full Text] [Related]
29. Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
Soukup V; Babjuk M; Dusková J; Pesl M; Szakáczová M; Zámecník L; Dvorácek J
Urol Int; 2008; 80(4):413-8. PubMed ID: 18587253
[TBL] [Abstract][Full Text] [Related]
30. Promoter methylation profile in preneoplastic and neoplastic gallbladder lesions.
García P; Manterola C; Araya JC; Villaseca M; Guzmán P; Sanhueza A; Thomas M; Alvarez H; Roa JC
Mol Carcinog; 2009 Jan; 48(1):79-89. PubMed ID: 18543280
[TBL] [Abstract][Full Text] [Related]
31. Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene P53 (TP53) in patients with bladder cancer.
Ecke TH; Lenk SV; Schlechte HH; Loening SA
Anticancer Res; 2003; 23(2A):957-62. PubMed ID: 12820330
[TBL] [Abstract][Full Text] [Related]
32. [Mechanism of p53 gene mutation in the development of urologic cancer].
Ye DW; Zheng JF; Qian SX
Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):656-8, 708. PubMed ID: 7866897
[TBL] [Abstract][Full Text] [Related]
33. BRCA1 promoter methylation associated with poor survival in Chinese patients with sporadic breast cancer.
Chen Y; Zhou J; Xu Y; Li Z; Wen X; Yao L; Xie Y; Deng D
Cancer Sci; 2009 Sep; 100(9):1663-7. PubMed ID: 19522853
[TBL] [Abstract][Full Text] [Related]
34. Promoter methylation of death-associated protein kinase and its role in irradiation response in cervical cancer.
Leung RC; Liu SS; Chan KY; Tam KF; Chan KL; Wong LC; Ngan HY
Oncol Rep; 2008 May; 19(5):1339-45. PubMed ID: 18425396
[TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic inactivation of Homeobox A5 gene in nonsmall cell lung cancer and its relationship with clinicopathological features.
Kim DS; Kim MJ; Lee JY; Lee SM; Choi JY; Yoon GS; Na YK; Hong HS; Kim SG; Choi JE; Lee SY; Park JY
Mol Carcinog; 2009 Dec; 48(12):1109-15. PubMed ID: 19554572
[TBL] [Abstract][Full Text] [Related]
37. A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer.
Christoph F; Hinz S; Kempkensteffen C; Weikert S; Krause H; Schostak M; Schrader M; Miller K
J Cancer Res Clin Oncol; 2007 Jun; 133(6):343-9. PubMed ID: 17160380
[TBL] [Abstract][Full Text] [Related]
38. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
39. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
40. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer.
Christoph F; Kempkensteffen C; Weikert S; Köllermann J; Krause H; Miller K; Schostak M; Schrader M
Br J Cancer; 2006 Dec; 95(12):1701-7. PubMed ID: 17133271
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
